The product push reflects a broader strategic pivot. Nestlé Health Science, which houses the Boost brand, is running structured consumer trials that measure how GLP-1 receptor agonists depress perception across all five basic taste qualities — a finding published in Physiology & Behavior. In response, the company is increasing pepper and spice levels in reformulated products and elevating protein and fiber across mainstream lines, such as a high-protein variant of the Milo chocolate malt drink. Nestlé is also involving GLP-1 users directly in recipe development as co-creators, a departure from standard R&D practice.
The companion-nutrition category is expanding rapidly. The number of packaged-food SKUs carrying "GLP-1 Friendly" labels rose approximately 37% from 2024, and the overall market for GLP-1-adjacent food and beverage products was valued at $3.88 billion in 2026. Broader industry forecasts project the GLP-1 drug impact on the food and beverage consumer market to grow from $4.6 billion in 2025 to $26.1 billion by 2034, a compound annual growth rate of 18.2%.
Nestlé positions its products as complements to, not replacements for, prescription GLP-1 agonists. The drugs remain far more potent appetite suppressants, and real-world discontinuation rates are high — about 65% of non-diabetic users stop within a year. That churn creates a recurring need for nutritional support during both weight-loss and maintenance phases, but it also limits the addressable population for companion products at any given moment.